CD274 and non-small cell lung carcinoma: A clinical trial of a combination therapy involving durvalumab and an anti-CTLA-4 antibody, tremelimumab, showed antitumor activity in NSCLC regardless of PD-L1 status, suggesting that this combination has therapeutic potential for patients with PD-L1-negative tumors31.